Health-related quality of life and economic implications of cutaneous T-cell lymphoma.

Abstract

Cutaneous T-cell lymphoma (CTCL) has been associated with considerable physical, psychological and financial burden. However, its impact on health-related quality of life (QoL) and economic costs are not well studied. To measure the QoL impact and financial burden of CTCL. A cross-sectional survey of 67 patients with CTCL was conducted using the Ontario Health Utilities Index Mark 3 (HUI3) questionnaire. Normative population data (n = 3310) were obtained from the 2002-2003 Joint Canada/United States Survey of Health. Economic cost was estimated using quality-adjusted life-year (QALY) loss derived from HUI3 scores. Patients with CTCL had significantly lower aggregate HUI3 scores than the general population (0·68 vs. 0·87, P<0·001). Multivariable regression analysis adjusting for demographics and comorbidities showed CTCL was associated with significantly poorer performance overall (-0·13, 95% CI -0·21 to -0·06, P<0·001) and in domains of speech (-0·03, 95% CI -0·05 to -0·01, P=0·01), ambulation (-0·04, 95% CI -0·08 to 0·00, P=0·03), emotion (-0·07, 95% CI -0·12 to -0·02, P=0·01), and pain (-0·07, 95% CI -0·13 to -0·01, P=0·03). These health utility decrements yielded an average loss of 1·48 QALYs per patient. Using a $50000 per QALY willingness-to-pay threshold, CTCL was associated with an individual lifetime burden of $73889 and U.S. societal burden of $2·86 billion. These findings suggest CTCL has a pervasive impact on QoL, comparable with debilitating conditions such as end-stage renal disease. The substantial economic burden of CTCL underscores the potential societal benefit of prompt diagnosis and effective management. What's already known about this topic? Cutaneous T-cell lymphoma is associated with physical, psychological and financial burden. What does this study add? The overall quality-of-life impact of cutaneous T-cell lymphoma has not previously been measured using a generic health utility instrument. In this study, we compare the overall quality-of-life burden of patients with cutaneous T-cell lymphoma with that of other populations and calculate the economic burden of the disease.